Statements (73)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:annual_report |
published regularly
|
| gptkbp:biopharmaceutical_sector |
active participant
|
| gptkbp:biotech_industry |
part of the growing sector
|
| gptkbp:business_model |
partnerships and collaborations
|
| gptkbp:ceo |
gptkb:Joseph_A._Yanchik_III
Dr. Manuel Aivado |
| gptkbp:clinical_trial |
gptkb:pharmaceuticals
gptkb:ALRN-6924 Phase 1, Phase 2, Phase 3 Phase 1 and Phase 2 promising results conducted globally reported in scientific journals focused on safety and efficacy aimed at unmet medical needs |
| gptkbp:collaboration |
gptkb:University_of_California,_San_Francisco
academic institutions |
| gptkbp:collaborations |
various pharmaceutical companies
with universities |
| gptkbp:community_engagement |
active in local biotech community
|
| gptkbp:drug_discovery |
innovative approaches
|
| gptkbp:financial_performance |
tracked by analysts
|
| gptkbp:focus |
therapeutics for cancer
developing stapled peptide therapeutics |
| gptkbp:founded |
gptkb:2008
|
| gptkbp:founder |
Joseph A. Zubiate
|
| gptkbp:funding |
gptkb:venture_capital
over $100 million sourced from various investors |
| gptkbp:future_plans |
expand clinical trials
|
| gptkbp:has_advisory_board |
composed of industry experts
|
| gptkbp:headquarters |
gptkb:Cambridge,_Massachusetts
|
| gptkbp:healthcare |
central to mission.
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aileron Therapeutics
|
| gptkbp:instruction_set |
multiple drug candidates
oncology drugs |
| gptkbp:invention |
multiple granted patents
|
| gptkbp:investment |
gptkb:New_Enterprise_Associates
Venture capital firms conducted periodically engaged with investors |
| gptkbp:investment_focus |
oncology
|
| gptkbp:ipo |
gptkb:2018
|
| gptkbp:lead_candidate |
gptkb:ALRN-6924
|
| gptkbp:marketing_strategy |
focused on innovation and collaboration
focused on oncology therapeutics |
| gptkbp:mechanism_of_action |
inhibiting MDM2 and MDMX
|
| gptkbp:partnership |
gptkb:Bristol-Myers_Squibb
collaborative approach |
| gptkbp:partnerships |
with leading research institutions
|
| gptkbp:publications |
numerous
|
| gptkbp:regulatory_compliance |
gptkb:FDA
filed with FDA |
| gptkbp:research |
driven by innovation
|
| gptkbp:research_and_development |
ongoing
|
| gptkbp:research_areas |
immuno-oncology
in various stages of development targeting oncogenic pathways |
| gptkbp:research_focus |
protein-protein interactions
p53 pathway |
| gptkbp:social_responsibility |
committed to ethical practices
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
no |
| gptkbp:stock_symbol |
not applicable
|
| gptkbp:strategic_goals |
advancing drug candidates
|
| gptkbp:targets |
gptkb:Oncology
|
| gptkbp:team |
experienced professionals
|
| gptkbp:technology |
Stapled Peptide Technology
stapled peptides |
| gptkbp:website |
www.aileronrx.com
|
| gptkbp:bfsParent |
gptkb:MPM_Capital
|
| gptkbp:bfsLayer |
6
|